ASMB Assembly Biosciences Inc.

13.36
-0.23  -2%
Previous Close 13.59
Open 13.61
Price To Book 1.8
Market Cap 342,029,079
Shares 25,600,979
Volume 20,537
Short Ratio
Av. Daily Volume 252,411

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
VEN 307 (diltiazem cream)
Anal fissures
Phase 2a 24-week data with with Nuc therapy due 4Q 2019.
ABI-H0731
Hepatitis B virus (HBV)
Phase 1b data due 1Q 2020.
ABI-H2158
Hepatitis B virus (HBV)
Phase 1b initiation of dosing announced June 27, 2019.
ABI-M201
Ulcerative Colitis

Latest News

  1. Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis
  2. Assembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit
  3. Assembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China
  4. Here’s What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
  5. Read This Before Selling Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares
  6. Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
  7. Assembly Biosciences: 1Q Earnings Snapshot
  8. Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
  9. The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
  10. Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
  11. Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development
  12. Here's Why Assembly Biosciences Is Slipping Today
  13. Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
  14. Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
  15. 4 Biotech Stocks With Major Catalysts in April
  16. Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
  17. Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit
  18. If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today
  19. Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results